ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 172

A Systematic Review and Meta-Analysis of Antibiotic Treatment for Reactive Arthritis

Claire E. Barber1, Joseph Kim2, Robert D. Inman3, John Esdaile4 and Matthew T. James5, 1Rheumatology, University of Calgary, Calgary, AB, Canada, 2Medicine, University of Calgary, Calgary, Canada, 3Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4Medicine, University of British Columbia, Vancouver, BC, Canada, 5Medicine, Univeristy of Calgary, Calgary, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Antibiotics, meta-analysis and reactive arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Infection-related Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Although bacterial infections are a common precipitant, it is unclear whether antibiotic treatment is effective for reactive arthritis. The purpose of this study was to conduct a systematic review and meta-analysis of randomized controlled trials to examine the efficacy and safety of antibiotic treatments for reactive arthritis. 

Methods: Medline, Embase, Pubmed, Cochrane CENTRAL Register of Controlled trials were searched up to November 2011 using MeSH terms and keywords pertaining to two major themes: reactive arthritis and antibiotic therapy.Randomized controlled trials of antibiotic use for reactive arthritis reporting on: remission, joint counts, pain or patient global scores were included. Two reviewers independently extracted information on the definition of reactive arthritis, features of study quality, type of treatment and outcomes. Pooled relative risks for binary outcomes (failure to achieve remission and adverse events) and pooled mean differences for continuous variables (joint counts, pain and patient global scores) were computed. Potential sources of heterogeneity were investigated using stratified analyses and meta-regression.

Results:

Twelve trials were eligible for inclusion and 10 provided adequate data for meta-analysis. The pooled relative risk of failure to achieve remission from a random effects model showed no significant benefit of antibiotic treatment (seven trials, 375 participants RR 0.74, 95% CI 0.49-1.10); however, substantial heterogeneity was observed (I2=76.3%, p<0.0001). The treatment effect did not significantly differ by the type of organism triggering the reactive arthritis (Chlamydia versus other), use of combination versus mono-therapy, or risk of bias. However, when only blinded trials were pooled, the treatment effect was attenuated and heterogeneity decreased significantly (RR 0.87, 95% CI 0.70-1.10, I2=32.8%, p=0.19). No significant effects of antibiotic treatment were observed on swollen joint counts (six trials, 375 participants weighted mean difference 0.21, 95% CI 1.16, 0.75, I2= 82.9%, p<0.0001) tender joint counts (five trials, 326 participants, standardized mean difference 0.10, 95% CI -0.58, 0.78, I2 86.9%, p<0.0001), pain (three trials, 220 participants, standardized mean difference 0.16, 95% CI -0.15, 0.46, I2 12.6%, p= 0.381), or patient global scores (four trials, 284 participants, standardized mean difference 0.15, 95% CI -0.08, 0.39, I2 0.0%, p= 0.499); however, antibiotics were associated with a 97% increase in gastrointestinal adverse events.

Conclusion: Trials of antibiotic treatment for reactive arthritis have produced heterogeneous results which may be related to differences in study quality.  The current evidence base does not support the use of antibiotics in routine clinical practice for the management of reactive arthritis.


Disclosure:

C. E. Barber,
None;

J. Kim,
None;

R. D. Inman,
None;

J. Esdaile,
None;

M. T. James,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-systematic-review-and-meta-analysis-of-antibiotic-treatment-for-reactive-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology